$3.15
+0.16(5.26%)
Mkt Cap $8M
$2.71
$37.65
52-Week Range
At a Glance
AI-generatedImunon narrowed operating and net losses in FY2025 through disciplined cost management including lower employee and consulting expenses, but EPS deteriorated sharply and cash burn persists amid clinical development demands and liquidity constraints.
8-K
Imunon reported a 2025 net loss of $14.5 million and provided positive final Phase 2 survival data for IMNN-001, showing a median overall survival increase of 14.7 months.$8M
Market Cap
—
Revenue
-$12M
Net Income
Employees25
Fundamentals
How The Business Makes Money
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0000749647
ISINUS15117N7012
CUSIP15117N701
Phone609 896 9100
Address997 Lenox Drive, Lawrenceville, NJ, 08648, US
SEC EDGAR